The company’s strong performance was underpinned by sustained demand for its core portfolio, particularly Xywav and Epidiolex, which saw year-over-year revenue growth of 13% and 16% respectively. CEO Renee Gala credited the results to operational momentum and strategic commercial execution across the business. The firm added approximately 525 net patients for Xywav during the quarter, bringing the total base of active patients to over 17,000.
Looking toward the immediate future, Jazz is positioning itself for the potential FDA approval of its gastroesophageal adenocarcinoma treatment, Ziihera, which carries a target action date of August 25, 2026. Beyond the launch, the company is actively expanding its R&D footprint, including a new preclinical collaboration with AbCellera Biologics to develop multispecific antibodies for solid tumors. Despite the positive revenue trajectory, the firm remains focused on streamlining its oncology pipeline, with plans to submit a labeling supplement to remove the second-line indication for Zepzelca in metastatic small-cell lung cancer following recent trial outcomes.
Comments (0)
No comments yet. Be the first!